Xinwei Hua Selected Research

Colorectal Neoplasms (Colorectal Cancer)

11/2023	Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
11/2022	Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis.
1/2022	Genome-wide association study identifies tumor anatomical site-specific risk variants for colorectal cancer survival.
1/2022	Genetic variants associated with circulating C-reactive protein levels and colorectal cancer survival: Sex-specific and lifestyle factors specific associations.
1/2021	Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients.
1/2021	Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study.
12/2020	Genetic Variants in the Regulatory T cell-Related Pathway and Colorectal Cancer Prognosis.
7/2020	Associations between molecular characteristics of colorectal serrated polyps and subsequent advanced colorectal neoplasia.
11/2019	Type 2 diabetes mellitus, blood cholesterol, triglyceride and colorectal cancer risk in Lynch syndrome.
8/2017	Timing of Aspirin and Other Nonsteroidal Anti-Inflammatory Drug Use Among Patients With Colorectal Cancer in Relation to Tumor Markers and Survival.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xinwei Hua Research Topics

Disease

10	Colorectal Neoplasms (Colorectal Cancer) 11/2023 - 08/2017
4	Colonic Neoplasms (Colon Cancer) 11/2023 - 11/2019
4	Neoplasms (Cancer) 01/2021 - 08/2014
2	Heart Failure 01/2023 - 01/2023
1	Insulin Resistance 01/2023
1	Hyperglycemia 01/2023
1	Inflammation (Inflammations) 01/2021
1	Adenoma (Adenomas) 07/2020
1	Polyps 07/2020
1	Type 2 Diabetes Mellitus (MODY) 11/2019
1	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 11/2019
1	Diabetes Mellitus 11/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2014

Drug/Important Bio-Agent (IBA)

3	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2023 - 01/2021
2	Triglycerides (Triacylglycerol)IBA 01/2023 - 11/2019
2	C-Reactive ProteinIBA 01/2022 - 01/2021
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2021
1	Glucose (Dextrose)FDA LinkGeneric 01/2023
1	Blood Glucose (Blood Sugar)IBA 01/2023
1	Genetic Markers (Genetic Marker)IBA 01/2022
1	Cetuximab (Erbitux)FDA Link 01/2021
1	Fluorouracil (Carac)FDA LinkGeneric 01/2021
1	Interleukin-7 (Interleukin 7)IBA 12/2020
1	betaglycan (TGFBR3)IBA 12/2020
1	DNA (Deoxyribonucleic Acid)IBA 07/2020
1	Epithelial Cell Adhesion MoleculeIBA 11/2019
1	CholesterolIBA 11/2019
1	ORALIT (ORS)IBA 09/2019
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 08/2017
1	Tumor Biomarkers (Tumor Markers)IBA 08/2017
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 08/2017
1	succinylated wheat germ agglutininIBA 08/2014

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 11/2023 - 11/2022
2	Patient Readmission 01/2023 - 01/2023
2	Therapeutics 11/2020 - 08/2014
1	Treatment Delay 01/2021